Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
April 2021
-
Press Release
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra… -
Story Access to Healthcare
Bringing Chagas disease to people’s attention
Explaining Chagas disease through the stories of patients in Bolivia.
-
Featured News
World Chagas Disease Day 2021
March 2021
-
Press Release
Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that… -
Press Release
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad… -
Key Release
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive… -
Featured News
Novartis inaugurates innovative watershed project in India to increase water availability
Together with local partners, Novartis aims to initiate a watershed development project near its own and supply chain operations in the Telangana region.
-
Story Access to Healthcare
Novartis joins pharma-wide effort to meet global demand for COVID-19 vaccines
A conversation with Joachim Momm, head of a Novartis manufacturing site that will be helping to produce Pfizer-BioNTech vaccine doses.
-
Key Release
Novartis appoints Karen Hale as Chief Legal Officer
Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive… -
Featured News
Highlights from the Co-Creating Impact Summit 2020
The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.
-
Press Release
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,… -
Key Release
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed…